Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Share Price |
Shares Traded |
Shares Owned |
Own chg |
Value Traded |
1d ret |
1w ret |
1m ret |
6m ret |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2018-08-15 | DRNA | Dicerna Pharmaceuticals Inc | Langer Dennis | Dir | S - Sale | $16.00 | -38,341 | 77,042 | -33% | -$613,456 | ||||||
| D | 2018-08-17 | CORI | Corium International, Inc. | Sweemer Timothy D | Chief Accounting Officer | S - Sale+OE | $9.01 | -346 | 34,801 | -1% | -$3,117 | |||||
| D | 2018-08-17 | CORI | Corium International, Inc. | Singh Parminder | CTO, VP, R, D | S - Sale+OE | $9.01 | -3,133 | 15,870 | -16% | -$28,224 | |||||
| D | 2018-08-17 | CORI | Corium International, Inc. | Sarret Joseph J. | Chief Business Officer | S - Sale+OE | $9.01 | -3,565 | 16,210 | -18% | -$32,116 | |||||
| D | 2018-08-17 | CORI | Corium International, Inc. | Breuil Robert S | CFO | S - Sale+OE | $9.01 | -972 | 14,441 | -6% | -$8,756 | |||||
| DM | 2018-08-16 | CORI | Corium International, Inc. | Staple Peter D | Pres, CEO | S - Sale+OE | $8.81 | -76,341 | 282,747 | -21% | -$672,524 | |||||
| D | 2018-08-15 | CORI | Corium International, Inc. | Thomas Robert | Dir | S - Sale+OE | $8.86 | -35,608 | 0 | -100% | -$315,476 | |||||
| M | 2016-05-18 | BSTC | Biospecifics Technologies Corp | Estate of Edwin H. Wegman | 10% | S - Sale | $38.22 | -57,705 | 947,473 | -6% | -$2,205,474 | |||||
2018-08-17 | BSTC | Biospecifics Technologies Corp | Wegman Toby | Dir, 10% | S - Sale | $51.89 | -2,500 | 947,473 | 0% | -$129,728 | ||||||
| M | 2018-08-16 | BSTC | Biospecifics Technologies Corp | Wegman Thomas | Pres, 10% | S - Sale | $51.30 | -23,592 | 1,238,800 | -2% | -$1,210,294 | |||||
| M | 2018-08-16 | LGND | Ligand Pharmaceuticals Inc | Aryeh Jason | Dir | S - Sale | $241.94 | -27,942 | 115,535 | -19% | -$6,760,159 | |||||
| M | 2018-08-16 | LGND | Ligand Pharmaceuticals Inc | Davis Todd C | Dir | S - Sale | $239.78 | -9,000 | 45,056 | -17% | -$2,158,002 | |||||
| DM | 2018-08-16 | LGND | Ligand Pharmaceuticals Inc | Higgins John L | CEO | S - Sale+OE | $241.96 | -34,500 | 88,919 | -28% | -$8,347,560 | |||||
| D | 2018-08-16 | LGND | Ligand Pharmaceuticals Inc | Patel Sunil | Dir | S - Sale+OE | $240.05 | -42,287 | 24,524 | -63% | -$10,150,808 | |||||
| D | 2018-08-17 | XNCR | Xencor Inc | Foster Paul A | Chief Medical Officer | S - Sale+OE | $40.10 | -3,659 | 4,952 | -42% | -$146,726 | |||||
2018-08-16 | CLRB | Cellectar Biosciences, Inc. | Longcor Jarrod | Chief Business Officer | P - Purchase | $2.71 | +500 | 7,200 | +7% | +$1,355 | ||||||
| D | 2018-08-16 | FGEN | Fibrogen Inc | Rosenkranz Roberto Pedro | Dir | S - Sale+OE | $60.28 | -1,000 | 32,700 | -3% | -$60,279 | |||||
| D | 2018-08-16 | FGEN | Fibrogen Inc | Kurkijarvi Kalevi | Dir | S - Sale+OE | $60.28 | -4,000 | 23,700 | -14% | -$241,128 | |||||
| D | 2018-08-15 | ARNA | Arena Pharmaceuticals Inc | Spector Steven W | EVP, GC, Sec | S - Sale+OE | $36.01 | -29,005 | 19,690 | -60% | -$1,044,505 | |||||
2018-08-15 | ACRS | Aclaris Therapeutics, Inc. | Tullman Stephen A. | Dir | P - Purchase | $15.97 | +6,250 | 557,771 | +1% | +$99,813 | ||||||
2018-08-15 | ARRY | Array Biopharma Inc | Haddock Jason | CFO | S - Sale | $13.92 | -20,000 | 35,393 | -36% | -$278,400 | ||||||
| D | 2018-08-15 | ARRY | Array Biopharma Inc | Van Lunsen Gil J | Dir | S - Sale+OE | $13.92 | -21,500 | 19,297 | -53% | -$299,280 | |||||
| DM | 2018-08-15 | ATNX | Athenex, Inc. | Zhang Song-Yi | Dir, 10% | S - Sale+OE | $16.65 | -105,052 | 6,708,917 | -2% | -$1,749,363 | |||||
2018-08-16 | UTHR | United Therapeutics Corp | Giltner Richard | Dir | S - Sale | $129.38 | -3,240 | 0 | -100% | -$419,198 | ||||||
2018-08-16 | AMPH | Amphastar Pharmaceuticals, Inc. | Peters William J | CFO, SVP, Treasurer | S - Sale | $17.59 | -2,407 | 86,836 | -3% | -$42,333 | ||||||
2018-08-17 | STDY | Steadymed Ltd. | Rigby Jonathan | Pres, CEO | S - Sale | $4.66 | -88,831 | 46,565 | -66% | -$413,739 | ||||||
| M | 2018-08-15 | INFI | Infinity Pharmaceuticals, Inc. | Kutok Jeffery | Chief Scientific Officer | S - Sale | $2.00 | -14,313 | 9,542 | -60% | -$28,687 | |||||
2018-08-16 | LLY | Lilly Eli & Co | Lilly Endowment Inc | 10% | S - Sale | $104.50 | -200,000 | 120,355,804 | 0% | -$20,899,800 | ||||||
| D | 2018-08-15 | GTHX | G1 Therapeutics, Inc. | Malik Rajesh | Ch. Medical Officer, SVP R, D | S - Sale+OE | $55.89 | -3,776 | 8,400 | -31% | -$211,023 | |||||
| D | 2018-08-15 | GTHX | G1 Therapeutics, Inc. | Velleca Mark A. | Pres, CEO | S - Sale+OE | $55.88 | -5,000 | 9,000 | -36% | -$279,378 | |||||
2018-08-14 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.02 | +58,200 | 25,567,198 | 0% | +$1,153 | ||||||
2018-08-14 | OVID | Ovid Therapeutics Inc. | Bernstein Karen | Dir | P - Purchase | $6.23 | +10,000 | 10,000 | New | +$62,300 | ||||||
2018-08-14 | OVID | Ovid Therapeutics Inc. | Williams Douglas E | Dir | P - Purchase | $6.49 | +5,000 | 5,000 | New | +$32,442 | ||||||
| M | 2018-08-14 | BLPH | Bellerophon Therapeutics, Inc. | Venrock Associates IV L P | 10% | P - Purchase | $0.65 | +529,370 | 6,541,163 | +9% | +$342,879 | |||||
| DM | 2018-08-14 | XNCR | Xencor Inc | Foster Paul A | Chief Medical Officer | S - Sale+OE | $41.10 | -36,341 | 4,952 | -88% | -$1,493,710 | |||||
| M | 2018-08-14 | BLPH | Bellerophon Therapeutics, Inc. | Venrock Associates IV L P | 10% | P - Purchase | $0.65 | +529,370 | 6,541,163 | +9% | +$342,879 | |||||
| M | 2018-08-14 | TBPH | Theravance Biopharma, Inc. | Gala Renee D | SVP, CFO | S - Sale | $26.79 | -43,743 | 171,049 | -20% | -$1,171,791 | |||||
2018-08-15 | JAZZ | Jazz Pharmaceuticals Plc | Young Matthew P. | EVP, CFO | S - Sale | $176.05 | -700 | 34,168 | -2% | -$123,235 | ||||||
| M | 2018-08-14 | CORT | Corcept Therapeutics Inc | Baker G Leonard Jr | Dir | P - Purchase | $12.48 | +179,686 | 4,525,213 | +4% | +$2,241,967 | |||||
| M | 2018-08-14 | RCUS | Arcus Biosciences, Inc. | Rosen Terry J | CEO | P - Purchase | $12.64 | +28,401 | 4,112,467 | +1% | +$359,127 | |||||
| D | 2018-08-15 | PCRX | Pacira Pharmaceuticals, Inc. | Stack David M | CEO, COB | S - Sale+OE | $47.32 | -33,062 | 111,487 | -23% | -$1,564,432 | |||||
2018-08-14 | PCRX | Pacira Pharmaceuticals, Inc. | Williams Kristen Marie | CAO, GC | S - Sale | $47.04 | -4,773 | 22,374 | -18% | -$224,522 | ||||||
| M | 2018-08-14 | VRCA | Verrica Pharmaceuticals Inc. | White Ted | Pres, CEO | P - Purchase | $15.69 | +2,505 | 7,005 | +56% | +$39,310 | |||||
2018-08-14 | JAZZ | Jazz Pharmaceuticals Plc | Miller Michael Patrick | EVP, US Commercial | S - Sale | $175.70 | -200 | 25,572 | -1% | -$35,140 | ||||||
| D | 2018-08-15 | ZTS | Zoetis Inc. | Knupp Catherine A. | EVP | S - Sale+OE | $90.84 | -46,816 | 34,824 | -57% | -$4,252,765 | |||||
2018-08-14 | ALBO | Albireo Pharma, Inc. | Cooper Ronald Harold Wilfred | Pres, CEO | P - Purchase | $31.85 | +788 | 6,734 | +13% | +$25,098 | ||||||
| M | 2018-08-14 | ALRN | Aileron Therapeutics Inc | Novartis Bioventures Ltd | 10% | S - Sale | $2.21 | -5,935 | 2,434,778 | 0% | -$13,123 | |||||
2018-08-14 | ZYME | Zymeworks Inc. | Lilly Eli & Co | 10% | S - Sale | $14.28 | -3,000 | 3,926,606 | 0% | -$42,840 | ||||||
2018-08-14 | PRGO | Perrigo Co Plc | Andersen Svend | EVP, Pres CHCI | P - Purchase | $69.43 | +7,200 | 7,200 | New | +$499,896 | ||||||
| M | 2018-08-14 | RDUS | Radius Health, Inc. | Biotech Growth N V | 10% | P - Purchase | $20.83 | +169,363 | 6,530,276 | +3% | +$3,528,410 | |||||
2018-08-15 | LLY | Lilly Eli & Co | Lilly Endowment Inc | 10% | S - Sale | $103.23 | -151,793 | 120,555,804 | 0% | -$15,669,440 | ||||||
2018-08-13 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.03 | +53,000 | 25,508,998 | 0% | +$1,378 | ||||||
| M | 2018-08-07 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.03 | +48,500 | 25,455,998 | 0% | +$1,402 | |||||
2018-08-15 | SRPT | Sarepta Therapeutics, Inc. | Ingram Douglas S | Pres, CEO | P - Purchase | $125.26 | +16,000 | 399,250 | +4% | +$2,004,211 | ||||||
2018-08-15 | KERX | Keryx Biopharmaceuticals Inc | Holmes Scott A | CFO | S - Sale | $3.04 | -1,185 | 165,365 | -1% | -$3,602 | ||||||
2018-08-15 | KERX | Keryx Biopharmaceuticals Inc | Neylan John F. | Chief Medical Officer | S - Sale | $3.04 | -1,186 | 150,688 | -1% | -$3,605 | ||||||
| DM | 2018-08-13 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $49.75 | -30,000 | 30,000 | -50% | -$1,492,600 | |||||
| DM | 2018-08-13 | PAHC | Phibro Animal Health Corp | Bfi Co., LLC | 10% | S - Sale+OE | $49.75 | -30,000 | 30,000 | -50% | -$1,492,600 | |||||
| M | 2018-08-14 | BSTC | Biospecifics Technologies Corp | Wegman Thomas | Pres | S - Sale | $50.81 | -23,908 | 312,419 | -7% | -$1,214,703 | |||||
| M | 2018-08-13 | NKTR | Nektar Therapeutics | Winger Dennis L | Dir | S - Sale | $60.59 | -34,250 | 47,750 | -42% | -$2,075,379 | |||||
| M | 2018-08-14 | EVFM | Evofem Biosciences, Inc. | Lynch Thomas G | Dir | P - Purchase | $2.26 | +100,000 | 175,000 | +133% | +$225,854 | |||||
| M | 2018-08-13 | ODT | Odonate Therapeutics, Inc. | Tang Kevin C | CEO, 10% | P - Purchase | $18.93 | +22,810 | 12,435,148 | 0% | +$431,705 | |||||
| DM | 2018-08-13 | LOXO | Loxo Oncology, Inc. | Van Naarden Jacob | Chief Business Officer | S - Sale+OE | $159.34 | -10,000 | 13,700 | -42% | -$1,593,446 | |||||
| DM | 2018-08-13 | LOXO | Loxo Oncology, Inc. | Burstein Jennifer | SVP of Finance | S - Sale+OE | $159.24 | -2,500 | 0 | -100% | -$398,105 | |||||
| DM | 2018-08-13 | LOXO | Loxo Oncology, Inc. | Bilenker Joshua H. | Pres, CEO | S - Sale+OE | $159.41 | -20,000 | 165,407 | -11% | -$3,188,181 | |||||
2018-08-14 | OCUL | Ocular Therapeutix, Inc | Notman Donald | CFO | P - Purchase | $6.29 | +12,500 | 17,300 | +260% | +$78,625 | ||||||
| D | 2018-08-13 | CTXR | Citius Pharmaceuticals, Inc. | Mazur Leonard L | Exec COB, 10% | P - Purchase | $1.27 | +3,137,255 | 6,855,595 | +84% | +$4,000,000 | |||||
| D | 2018-08-13 | CTXR | Citius Pharmaceuticals, Inc. | Holubiak Myron Z | Pres, CEO, 10% | P - Purchase | $1.27 | +784,314 | 1,304,196 | +151% | +$1,000,000 | |||||
| D | 2018-08-13 | VCNX | Vaccinex, Inc. | Friedberg Albert | Dir, 10% | P - Purchase | $12.00 | +2,458,333 | 5,848,990 | +73% | +$29,499,996 | |||||
2018-06-19 | VRCA | Verrica Pharmaceuticals Inc. | White Ted | Pres, CEO | P - Purchase | $15.00 | +4,500 | 4,500 | New | +$67,500 | ||||||
2018-06-19 | VRCA | Verrica Pharmaceuticals Inc. | Palczuk Linda | COO | P - Purchase | $15.00 | +3,000 | 3,000 | New | +$45,000 | ||||||
2018-06-19 | VRCA | Verrica Pharmaceuticals Inc. | Degnan Chris | CFO | P - Purchase | $15.00 | +3,000 | 3,000 | New | +$45,000 | ||||||
2018-06-19 | VRCA | Verrica Pharmaceuticals Inc. | Bonaccorso Joe | Chief Commercial Officer | P - Purchase | $15.00 | +1,000 | 1,000 | New | +$15,000 | ||||||
2018-06-19 | VRCA | Verrica Pharmaceuticals Inc. | Manning Paul B | Dir, 10% | P - Purchase | $15.00 | +300,000 | 9,504,661 | +3% | +$4,500,000 | ||||||
2018-08-13 | ICUI | Icu Medical Inc/de | Pfizer Inc | Dir, 10% | S - Sale | $284.35 | -700,000 | 2,500,000 | -22% | -$199,045,000 | ||||||
| D | 2018-08-14 | AMPH | Amphastar Pharmaceuticals, Inc. | Prins Richard K | Dir | S - Sale+OE | $17.82 | -10,000 | 35,434 | -22% | -$178,180 | |||||
2018-08-14 | DOVA | Dova Pharmaceuticals, Inc. | Sapir Alex | Pres, CEO | P - Purchase | $22.83 | +21,700 | 68,609 | +46% | +$495,411 | ||||||
| M | 2018-08-13 | EBS | Emergent Biosolutions Inc. | El-Hibri Fuad | COB, 10% | S - Sale | $55.98 | -36,318 | 7,357,080 | 0% | -$2,033,109 | |||||
| D | 2018-08-14 | ZTS | Zoetis Inc. | Alaix Juan Ramon | CEO | S - Sale+OE | $91.55 | -135,000 | 96,013 | -58% | -$12,359,250 | |||||
2018-08-13 | BGNE | Beigene, Ltd. | Wang Xiaodong | Dir | S - Sale | $158.77 | -3,449 | 13,152,979 | 0% | -$547,591 | ||||||
2018-08-14 | ENDP | Endo International Plc | Kimmel Roger H | Dir | S - Sale | $15.90 | -26,074 | 265,277 | -9% | -$414,577 | ||||||
| A | 2018-08-13 | ABUS | Arbutus Biopharma Corp | Sofia Michael J. | Chief Scientific Officer | S - Sale | $9.51 | -4,250 | 1,670,565 | 0% | -$40,436 | |||||
2018-08-15 | OPTN | Optinose, Inc. | Gibbs Thomas Edward | Chief Commercial Officer | P - Purchase | $12.69 | +2,000 | 3,985 | +101% | +$25,380 | ||||||
2018-08-15 | CLSN | Celsion Corp | Fritz Frederick J. | Dir | P - Purchase | $2.39 | +5,500 | 27,841 | +25% | +$13,145 | ||||||
2018-08-15 | OPTN | Optinose, Inc. | Miller Peter K | CEO | P - Purchase | $14.32 | +10,752 | 117,738 | +10% | +$153,969 | ||||||
2018-08-10 | IMMY | Imprimis Pharmaceuticals, Inc. | Kammer Robert J | Dir | S - Sale | $3.00 | -130,000 | 929,827 | -12% | -$390,000 | ||||||
| D | 2018-08-10 | AVDL | Avadel Pharmaceuticals Plc | Anderson Michael S | CEO | S - Sale+OE | $4.91 | -16,297 | 248,953 | -6% | -$79,953 | |||||
| D | 2018-08-10 | AVDL | Avadel Pharmaceuticals Plc | Hatten Sandra L | See Remarks | S - Sale+OE | $4.91 | -6,290 | 47,410 | -12% | -$30,859 | |||||
2018-08-10 | ALRN | Aileron Therapeutics Inc | Longenecker John P Phd | Pres, CEO | P - Purchase | $2.45 | +10,000 | 10,000 | New | +$24,500 | ||||||
2018-08-10 | KPTI | Karyopharm Therapeutics Inc. | Chione Ltd | 10% | S - Sale | $18.50 | -702 | 8,261,561 | 0% | -$12,987 | ||||||
2018-08-13 | ABUS | Arbutus Biopharma Corp | Sofia Michael J. | Chief Scientific Officer | S - Sale | $9.51 | -4,250 | 1,670,565 | 0% | -$40,436 | ||||||
| M | 2018-08-13 | PETX | Aratana Therapeutics, Inc. | Heinen Ernst | Chief Development Officer | S - Sale | $5.15 | -10,372 | 155,694 | -6% | -$53,416 | |||||
| M | 2018-08-10 | ALRN | Aileron Therapeutics Inc | Novartis Bioventures Ltd | 10% | S - Sale | $2.42 | -7,215 | 2,440,713 | 0% | -$17,477 | |||||
| M | 2018-08-10 | ZYME | Zymeworks Inc. | Lilly Eli & Co | 10% | S - Sale | $14.32 | -6,429 | 3,929,606 | 0% | -$92,033 | |||||
2018-08-13 | PFE | Pfizer Inc | Olson Laurie J | EVP | S - Sale | $41.00 | -10,214 | 78,201 | -12% | -$418,774 | ||||||
| D | 2018-08-10 | VTVT | Vtv Therapeutics Inc. | Perelman Ronald O | 10% | P - Purchase | $4.38 | +570,777 | 4,898,771 | +13% | +$2,500,003 | |||||
2018-08-10 | VRCA | Verrica Pharmaceuticals Inc. | Manning Paul B | Dir, 10% | P - Purchase | $15.08 | +33,000 | 9,204,661 | 0% | +$497,640 | ||||||
| A | 2017-07-05 | ALRN | Aileron Therapeutics Inc | Kapnick Scott | Dir, 10% | P - Purchase | $15.00 | +66,666 | 66,666 | New | +$999,990 | |||||
2018-08-10 | ZGNX | Zogenix, Inc. | Perceptive Advisors LLC | 10% | P - Purchase | $52.00 | +100,000 | 4,070,357 | +3% | +$5,200,000 | ||||||
2018-08-13 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $5.33 | +15,000 | 191,702,326 | 0% | +$79,932 |
Real-time CSV? Options? Alerts? Contact us!
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |